Skip to main content
Fig. 1 | Molecular Cancer

Fig. 1

From: SOX2 dosage sustains tumor-promoting inflammation to drive disease aggressiveness by modulating the FOSL2/IL6 axis

Fig. 1

Somatic copy number alterations are associated with cancer aggressiveness. (A1) A bar plot presenting the percentage of cancer-related casualties in 27 cancer entities from the TCGA. Each bar represent a cancer entity and the green color represent the percentage of all patients who were reported alive at the last follow-up, while the red bars represent the percentage of patients who were confirmed dead at the last follow-up. (A2) A Kaplan–Meier overall survival curve for patients from the first 10 poor outcome cancer entities (red) and the last 5 better outcome entities (blue) (from Fig. 1a1). The survival time represent the time from first diagnosis to last follow-up. (A3) A histogram showing age distribution across all analyzed 27 cancer entities from the TCGA. The average age at first diagnosis for all cancer entities analyzed was ~ 58 years with a standard deviation of ~ 13 years. (A4) A bar plot presenting the fraction of patients who were diagnosed with cancer before or after 45 years. The cut-off of 45 years represents the mean age at diagnosis minus one standard deviation around the mean. (A5) A bar plot showing the tumor mutational burden in two of the most aggressive entities, where more than 10% of cases were diagnosed before 45 years of age. (B1) A correlation plot showing the correlation between the percentage of dead cases per entity and copy number alterations (CNA) as well as tumor mutational burden (TMB). The number of identified CNA (N° CNA) as well as the number of deletions (Del) or amplifications (Amp) and the number of amplified (Amp bp) or deleted base pairs (Amp bp) are presented. (B2) A bar plot showing the percentage of amplifications or deletion in each of the 27 cancer entities. (B3) representative CNV plots demonstrating higher copy number deletion. (B4) A circus plot showing the copy number alterations and mutations in TGCT for patients diagnosed before (left panel) and after (right panel) 45 years of age. TGCT is the entity with the highest number of patients diagnosed before 45 years of age. (C1) Bar plots showing the percentage of male and female cases diagnosed before the age of 45 years, for all cancer entities with more than 10% of cases diagnosed before 45 years of age. Gender-specific entities are not included here. (C2) Gaia CNV plots for ACC in females and males diagnosed before the age of 45 years, respectively. ACC is one of the entities with higher incidence in females before 45 years of age. (C3) A Kaplan–Meier overall survival curve for glioblastoma patients with and without IDH1 mutation (left) and A Kaplan–Meier overall survival curve for glioblastoma patients diagnosed before and after the age of 45 years (right). (C4) An oncoprint showing the top 20 most mutated genes in glioblastoma in patients diagnosed before the age of 45 years and an oncoprint showing the top 20 most mutated genes in glioblastoma in patients diagnosed after the age of 45 years. (D1) A heat map showing all genes with copy number amplifications and concomitant upregulation (log fold change ≥ 0.9, FDR < 0.05) in the top 10 most aggressive tumors. (D2) A variable of importance box plot for all gene with copy number amplifications and concomitant upregulation in the top 10 most aggressive tumors. (D3) Boxplots showing the transcript expression of SOX2-regulated genes. These genes are copy number amplified in poor outcome cancer and show concomitant upregulation. (D4) Accumulation of SOX2 peaks around its targets genes amplified and upregulated in poor outcome cancers. (D5) Kaplan–Meier overall survival plots for the top most significant genes in the multivariate model

Back to article page